Background

During the summer of 1997 several prominent cardiologists and representatives from Aventis Pharma (formerly known as Rhône-Poulenc Rorer) began discussions about setting up a research study into the management and outcomes of patients experiencing an acute coronary event. By the end of that year, activities for creation of the Global Registry of Acute Coronary Events - that would later become GRACE - were under way.

The implementation of lessons learnt in a pilot study, conducted in 1999, have assured that GRACE will become the gold standard registry that will stand the most intense scrutiny from the medical profession and ultimately improve patient outcomes.

Pilot Study

The Global Registry of Acute Coronary Events (GRACE) was officially launched in Barcelona, Spain on August 31, 1999 at the annual meeting of the European Society of Cardiology (ESC).

The GRACE registry is supported by an educational grant from Aventis Pharma (formerly known as Rhône-Poulenc Rorer), a leader in the field of antithrombotic medicine. GRACE aims to improve patient care by providing cardiologists with a greater understanding of patient management and outcomes in the rapidly evolving field of ACS treatment.